scholarly journals Safety and Efficacy of Tenofovir Alafenamide Fumarate in Early-Middle Pregnancy for Mothers With Chronic Hepatitis B

2022 ◽  
Vol 8 ◽  
Author(s):  
Ruochan Chen ◽  
Ju Zou ◽  
Liyuan Long ◽  
Haiyue Huang ◽  
Min Zhang ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Pregnant Women ◽  
Transmission Rate ◽  
Mother To Child Transmission ◽  
Child Transmission ◽  
B Virus ◽  
Tenofovir Alafenamide ◽  
Mother To Child

BackgroundTenofovir alafenamide fumarate has been used in late pregnancy; however, no data exist regarding its safety and effectiveness in early and middle pregnancy for mothers with hepatitis B virus infection.AimsTo design a prospective study to investigate the efficacy and safety of TAF in pregnant women with chronic HBV infection during early-middle pregnancy.MethodsPregnant women with active chronic hepatitis B who received tenofovir alafenamide fumarate during early and middle pregnancy were enrolled and followed up until 6 months postpartum. Infants received immunoprophylaxis. The primary endpoint was the safety of mothers and infants. The secondary endpoints were maternal hepatitis B virus DNA reduction at delivery and mother-to-child transmission rate.ResultsAmong 98 mothers enrolled, 31 initiated tenofovir alafenamide fumarate in early pregnancy, and 57 in middle pregnancy. The mean (± standard deviation) age was 29.00 (±3.81) years. At delivery, 100% (98/98) of the mothers achieved hepatitis B virus DNA levels <200,000 IU/L. Ninety-eight infants were born, and none had congenital defects or malformations. All infants received hepatitis B virus immunoprophylaxis. The mother-to-child transmission rate was 0%. Growth parameters including body weight, height, and head circumference were comparable to the national standards for physical development. No severe adverse effects were reported in either mothers or infants. No severe liver function damage occurred in any of the mothers.ConclusionsInitiating tenofovir alafenamide fumarate in early and middle pregnancy appears safe for both mothers and infants, and it is effective for controlling maternal disease as well as interrupting mother-to-child transmission.

scholarly journals A knowledge survey of obstetrics and gynecology staff on the prevention of mother-to-child transmission of hepatitis B virus

2013 ◽  
Vol 7 (05) ◽  
pp. 391-397 ◽  
Author(s):  
Yali Hu ◽  
Xinwei Dai ◽  
Yi-Hua Zhou ◽  
Huixia Yang
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Pregnant Women ◽  
Hepatitis B Surface Antigen ◽  
Mother To Child Transmission ◽  
Child Transmission ◽  
B Virus ◽  
Hepatitis B Immunoglobulin ◽  
Knowledge Survey ◽  
Mother To Child

Introduction: This survey was designed to investigate the knowledge awareness of obstetrics and gynaecology staff (Obs/Gyn staff) on the prevention of mother-to-child transmission (PMTCT) of hepatitis B virus (HBV). Methodology: Obs/Gyn staff from 21 of the 31 Chinese mainland provinces, who attended medical meetings or training classes from July to October 2011, were invited to complete a questionnaire regarding PMTCT of HBV. The questionnaire included the clinical implications of HBV serologic markers and PMTCT preventive measures for both pregnant women and infants. Results: A total of 828 questionnaires were distributed, 617 (74.5%) Obs/Gyn staff participated in the survey, and 559 (90.6%) questionnaires met the inclusion criteria. Overall, 90% of participants correctly determined the positive hepatitis B surface antigen (HBsAg) as infectious, but up to 27.5% mistakenly considered the presence of anti-HBe and/or anti-HBc with negative HBsAg as infectious. In total, 96.3% respondents knew that pregnant women should be screened for HBV infection, and 95.3% realized that infants of HBsAg-positive mothers should be injected with hepatitis B immunoglobulin and vaccine. On the other hand, with the available immunoprophylaxis, 13.8% participants mistakenly believed caesarean section may prevent HBV mother-to-child transmission, and only 13% correctly answered that newborns of HBsAg positive mothers may be breastfed. Conclusion: Obs/Gyn staff in China have mastered the strategies of HBV PMTCT, but there is obvious insufficiency in details of the application. Intensified efforts to train the Obs/Gyn staff are required to improve the current suboptimal medical service in HBV-exposed infants and to control mother-to-infant transmission of HBV.

scholarly journals Hepatitis B virus serosurvey and awareness of mother-to-child transmission among pregnant women in Shenyang, China

Medicine ◽  
2018 ◽  
Vol 97 (22) ◽  
pp. e10931 ◽  
Author(s):  
Qiu-Ju Sheng ◽  
Sui-Jing Wang ◽  
Yu-Yu Wu ◽  
Xiao-Guang Dou ◽  
Yang Ding
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Pregnant Women ◽  
Mother To Child Transmission ◽  
Child Transmission ◽  
B Virus ◽  
Mother To Child

scholarly journals Telbivudine Treatment during Late Pregnancy Prevents Mother-to-Child Transmission of Hepatitis B Virus: A Retrospective Study

2019 ◽  
Vol 2019 ◽  
pp. 1-9
Author(s):  
Mengzhi Cai ◽  
Yanli Hao ◽  
Jianxin Zhong ◽  
Wei Yao ◽  
Xia Cao ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Pregnant Women ◽  
Hepatitis B Surface Antigen ◽  
Late Pregnancy ◽  
Hbv Dna ◽  
Mother To Child Transmission ◽  
Child Transmission ◽  
B Virus ◽  
Mother To Child

Purpose. To investigate the efficacy of telbivudine (LdT) in blocking mother-to-child transmission (MTCT) of hepatitis B virus (HBV) during late pregnancy. Methods. A total of 651 pregnant women aged 18-40 in Nantong Third People’s Hospital and Hospital affiliated to Nantong University with positive hepatitis B surface antigen (HBsAg) and HBV DNA were enrolled between January 2011 and December 2015. Patients with HBV DNA≥106 copies/mL (n=251) received LdT during late pregnancy according to the patients’ will, while 136 high viral patients with HBV DNA≥106 copies/mL who did not take LdT therapy and 268 low viral patients with HBV DNA<106 copies/mL served as the controls. Results. At 7 months and 1 year postpartum, the basal HBV DNA serum level of treated patients declined significantly (P<0.001), while no obvious decline was observed in the untreated high viraemic controls (P<0.05) and untreated low viraemic controls (P<0.05). Only 1 infant (0.4%) in LdT group was HBsAg positive at 7 months, while 14 (5.2%) were in the untreated low viraemic controls (P<0.001) and 15 (11.0%) were in untreated high viraemic controls (P<0.001). Conclusion. For pregnant women with HBV DNA≥106 copies/mL, the use of LdT during late pregnancy could effectively reduce the MTCT rate of HBV.

Sign in / Sign up

Export Citation Format

Share Document